Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Kimberly-Clark's recent earnings for its fourth quarter and full year 2023 results showed both steady growth and challenges.</li><li>They are focused on elevating categories and expanding markets for growth, a strategy which is showing promising results.</li><li>The earnings call highlighted that the company had faced supply constraints that affected its market share.</li></ul>

Kimberly-Clark's recent earnings for its fourth quarter and full year 2023 results showed both steady growth and challenges.They are focused on elevating categories and expanding markets for growth, a strategy which is showing promising results.The earnings call highlighted that the company had faced supply constraints that affected its market share.

Kimberly-Clark Corporation: Optimized pricing and volume mix strategy could be a game changer? - Major Drivers

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/vinda-international-holdings-limited" target="_blank" data-smartkarma-citation="entities:475:1" rel="noopener">Vinda International (3331 HK)</a> has announced a pre-conditional voluntary offer from Sukanto Tanoto at HK$23.50 per scheme share, a 7.8% premium to the undisturbed price (26 April). </li>
<li>The pre-condition relates to China SAMR and Japan Fair Trade Commission approval. The offer is conditional on the offeror and concert parties representing more than 50% of voting rights.</li>
<li>Irrevocables ensure the satisfaction of the minimum acceptance condition but also rule out a competing proposal. The timing of China SAMR approval is the key risk. </li>
</ul>



Vinda International (3331 HK) has announced a pre-conditional voluntary offer from Sukanto Tanoto at HK$23.50 per scheme share, a 7.8% premium to the undisturbed price (26 April). 
The pre-condition relates to China SAMR and Japan Fair Trade Commission approval. The offer is conditional on the offeror and concert parties representing more than 50% of voting rights.
Irrevocables ensure the satisfaction of the minimum acceptance condition but also rule out a competing proposal. The timing of China SAMR approval is the key risk. 


Vinda International (3331 HK): Pre-Conditional Voluntary Offer at HK$23.50

<ul><li>Kimberly-Clark Corporation delivered mixed results for the previous quarter, with revenues below the analyst consensus.</li><li>The strategic exit from the Brazil tissue business had an additional effect, reducing net sales by 100 basis points, primarily affecting Consumer Tissue and the Professional business.</li><li>Consumer Tissue reported 2% organic growth, with North America delivering a strong 4% organic growth, driven by robust demand for dry baths and towels.</li></ul>

Kimberly-Clark Corporation delivered mixed results for the previous quarter, with revenues below the analyst consensus.The strategic exit from the Brazil tissue business had an additional effect, reducing net sales by 100 basis points, primarily affecting Consumer Tissue and the Professional business.Consumer Tissue reported 2% organic growth, with North America delivering a strong 4% organic growth, driven by robust demand for dry baths and towels.

Kimberly-Clark Corporation: Is It The Market’s Hidden Gem? - Major Drivers

<ul><li>Kimberly-Clark delivered mixed results for the previous quarter, with revenues below analyst expectations but managed an earnings beat.</li><li>The company delivered strong organic growth across all segments.</li><li>Significant progress was made on margin recovery, leading to increased adjusted gross margin, operating profit, and earnings per share.</li></ul>

Kimberly-Clark delivered mixed results for the previous quarter, with revenues below analyst expectations but managed an earnings beat.The company delivered strong organic growth across all segments.Significant progress was made on margin recovery, leading to increased adjusted gross margin, operating profit, and earnings per share.

Kimberly-Clark Corporation: Winning the Race in Key Markets Worldwide? – Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kenvue-inc" target="_blank" data-smartkarma-citation="entities:36755:1" rel="noopener">Kenvue (KVUE US)</a> reported 5% YoY revenue growth to $4B in 2Q23, driven by continued demand of self-care portfolio, mainly consisting of cough, cold, and allergy, and pain care products.</li>
<li>The company has guided for 4.5–5.5% revenue growth and EPS of $1.26–1.31 for 2023. Kenvue has declared a cash dividend of $0.20 for 3Q23.  </li>
<li>J&amp;J is offering its shareholders the option to exchange shares for Kenvue's at a 7% discount. The exchange offer is scheduled to close on August 18, 2023.</li>
</ul>



Kenvue (KVUE US) reported 5% YoY revenue growth to $4B in 2Q23, driven by continued demand of self-care portfolio, mainly consisting of cough, cold, and allergy, and pain care products.
The company has guided for 4.5–5.5% revenue growth and EPS of $1.26–1.31 for 2023. Kenvue has declared a cash dividend of $0.20 for 3Q23.  
J&amp;J is offering its shareholders the option to exchange shares for Kenvue's at a 7% discount. The exchange offer is scheduled to close on August 18, 2023.


Kenvue (KVUE US): Q2 Result Beats Estimates; Initiated 2023 Guidance; J&J Launches Exchange Offer

United States

Kimberly-Clark Corporation is a global health and hygiene company that manufactures and provides consumer products. The Company's products include diapers, tissues, paper towels, incontinence care products, surgical gowns, and disposable face masks.  Kimberly-Clark's products are sold in countries around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kimberly Clark (KMB US)

Kimberly-Clark Corporation: Optimized pricing and volume mix strategy could be a game changer? - Major Drivers

Kimberly-Clark's recent earnings for its fourth quarter and full year 2023 results showed both steady growth and challenges. They are focused on...

Baptista Research

Vinda International (3331 HK): Pre-Conditional Voluntary Offer at HK$23.50

Irrevocables ensure the satisfaction of the minimum acceptance condition but also rule out a competing proposal. The timing of China SAMR approval...

Arun George

Kimberly-Clark Corporation: Is It The Market’s Hidden Gem? - Major Drivers

Kimberly-Clark Corporation delivered mixed results for the previous quarter, with revenues below the analyst consensus. The strategic exit from...

Baptista Research

Kimberly-Clark Corporation: Winning the Race in Key Markets Worldwide? – Major Drivers

Kimberly-Clark delivered mixed results for the previous quarter, with revenues below analyst expectations but managed an earnings beat. The...

Baptista Research

Kenvue (KVUE US): Q2 Result Beats Estimates; Initiated 2023 Guidance; J&J Launches Exchange Offer

Kenvue beat Q2 sales and EPS estimates and guided for 4.5-5.5% sales growth for 2023. J&J is launching exchange offer for its holders to get ...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)